Reclast (Zoledronic Acid) Label Updates 2020 to 2026: FDA Safety Changes Explained
A review of what is publicly documented about Reclast (zoledronic acid) FDA labeling and safety themes since 2020, including renal monitoring, atypical femoral fracture, osteonecrosis of the jaw, and hypocalcemia language, with guidance on verifying the current Prescribing Information before use.